A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status:
Terminated
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study in participants with triple negative breast cancer
(TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of
SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B
(dose expansion).